Last reviewed · How we verify
NCT06143774
Study of TRX-920 for Patients With Advanced Solid Tumors
Phase 1 trial testing TRX-920 Oral Gel (10 mg and 30 mg) in Advanced Solid Tumor in 30 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | TaiRx, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 31 October 2023 |
| Primary completion | 31 December 2026 |
| Estimated completion | 15 June 2027 |
| Sites | 3 locations across Taiwan |
Drugs / interventions tested
- TRX-920 Oral Gel (10 mg and 30 mg) — full drug profile →
Conditions studied
- Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
Sponsor
TaiRx, Inc. — full company profile →
Who can join
Adults 18 to 100, any sex, with Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study drug TRX-920 Oral Gel contains SN38, an active metabolite of Irinotecan (CPT-11), which is a widely prescribed anti-cancer drug that has been approved in many countries for the treatment of colorectal and pancreatic cancer. TRX-920 is the oral gel formulation that directly contains SN38 instead of Irinotecan. A series of biology and animal studies have demonstrated that the TRX-920 Oral Gel could inhibit tumor growth with fewer side effects compared to Irinotecan.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06143774
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Solid Tumor
Currently open trials in the same condition.
- NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
- NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
- NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
- NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting
Other TaiRx, Inc. trials
Trials by the same sponsor.
- NCT07521852 — A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination Wi · Phase 2 · recruiting
- NCT05257590 — CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT04336124 — Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients · Phase 1 · completed
- NCT03600233 — Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors · Phase 2 · active not recruiting
- NCT03582618 — CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06143774 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by TaiRx, Inc.
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06143774.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing